4615 Amobarbital A barbiturate with hypnotic and sedative properties (but not antianxiety). Adverse effects are mainly a consequence of dose-related CNS depression and the risk of dependence with continued use is high. (From Martindale, The Extra Pharmacopoeia, 30th ed, p565) 57-43-2 2164 C11H18N2O3 226.27 White powder. 157 °C 603 mg/L (at 25 °C) Amobarbital (like all barbiturates) works by binding to the GABAA receptor at either the alpha or the beta sub unit. These are binding sites that are distinct from GABA itself and also distinct from the benzodiazepine binding site. Like benzodiazepines, barbiturates potentiate the effect of GABA at this receptor. This GABAA receptor binding decreases input resistance, depresses burst and tonic firing, especially in ventrobasal and intralaminar neurons, while at the same time increasing burst duration and mean conductance at individual chloride channels; this increases both the amplitude and decay time of inhibitory postsynaptic currents. In addition to this GABA-ergic effect, barbiturates also block the AMPA receptor, a subtype of glutamate receptor. Glutamate is the principal excitatory neurotransmitter in the mammalian CNS. Amobarbital also appears to bind neuronal nicotinic acetylcholine receptors. No indication of carcinogenicity to humans (not listed by IARC). 2014-08-30T21:04:32Z 2026-05-14T16:59:43Z Amobarbital C07536 2673 DB01351 true CCC1(CCC(C)C)C(=O)NC(=O)NC1=O C11H18N2O3 InChI=1S/C11H18N2O3/c1-4-11(6-5-7(2)3)8(14)12-10(16)13-9(11)15/h7H,4-6H2,1-3H3,(H2,12,13,14,15,16) VIROVYVQCGLCII-UHFFFAOYSA-N 226.2722 226.131742452 Exogenous Solid 2.07 CHEMBL267894 2079 CHEM003521 DTXSID9020081 NS00008808 5-ethyl-5-(3-methylbutyl)-1,3-diazinane-2,4,6-trione 75.27 58.0029 23.44849042106522 4 3 2 7.484748322088917 0 1 1.87 -2.40 8.97e-01 g/l